Sebastian Bernales is a Chilean venture capital investor at Humboldt Fund who served as VP of Discovery Biology at Medivation, helping develop the blockbuster prostate cancer drug Xtandi before the company's $14B acquisition by Pfizer. He specializes in globally distributed biotech development models, having structured companies with biology work in Chile, chemistry in India, and commercial operations in California, while maintaining deep connections between world-class US scientists and Latin America through initiatives like organizing yearly Science and Friendship trips that brought over 200 UCSF scientists to Chile. Sebastian Bernales is a Chilean venture capital investor at Humboldt Fund who served as VP of Discovery Biology at Medivation, helping develop the blockbuster prostate cancer drug Xtandi before the company's $14B acquisition by Pfizer. He specializes in globally distributed biotech development models, having structured companies with biology work in Chile, chemistry in India, and commercial operations in California, while maintaining deep connections between world-class US scientists and Latin America through initiatives like organizing yearly Science and Friendship trips that brought over 200 UCSF scientists to Chile.